Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Goldstein

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Diabetes|June 29, 2007
Comment on: Hattori et al. (2007) Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts: Diabetes 56:804-808Barry J Goldstein, Rosario Scalia, Xin L Ma, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 24, 2013
Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studiesSamuel S Engel, Elizabeth Round, Gregory T Golm, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2013
Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical StudiesSamuel S Engel, Elizabeth Round, Gregory T Golm, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 18, 2007
Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signalingXiangdong Wu, Kalyankar Mahadev, Lauren Fuchsel, et al.
Antioxidants & Redox Signaling|May 14, 2005
Hyperglycemia potentiates H(2)O(2) production in adipocytes and enhances insulin signal transduction: potential role for oxidative inhibition of thiol-sensitive protein-tyrosine phosphatasesXiangdong Wu, Li Zhu, Assaf Zilbering, et al.
Current Medical Research and Opinion|September 14, 2006
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-studyBarry J Goldstein, Peter N Weissman, Margaret J Wooddell, et al.
Diabetes Care|May 9, 2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesBarry J Goldstein, Mark N Feinglos, Jared K Lunceford, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 25, 2007
Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitroSrinivasa Raju Datla, Hitesh Peshavariya, Gregory J Dusting, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 23, 2008
Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: role of cAMP/PKA signalingShi-Qiong Xu, Kalyankar Mahadev, Xiangdong Wu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 31, 2015
Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trialsElizabeth S Ommen, Lei Xu, Edward A O'Neill, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Diabetes|June 29, 2007
Comment on: Hattori et al. (2007) Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts: Diabetes 56:804-808Barry J Goldstein, Rosario Scalia, Xin L Ma, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 24, 2013
Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studiesSamuel S Engel, Elizabeth Round, Gregory T Golm, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2013
Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical StudiesSamuel S Engel, Elizabeth Round, Gregory T Golm, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 18, 2007
Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signalingXiangdong Wu, Kalyankar Mahadev, Lauren Fuchsel, et al.
Antioxidants & Redox Signaling|May 14, 2005
Hyperglycemia potentiates H(2)O(2) production in adipocytes and enhances insulin signal transduction: potential role for oxidative inhibition of thiol-sensitive protein-tyrosine phosphatasesXiangdong Wu, Li Zhu, Assaf Zilbering, et al.
Current Medical Research and Opinion|September 14, 2006
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-studyBarry J Goldstein, Peter N Weissman, Margaret J Wooddell, et al.
Diabetes Care|May 9, 2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesBarry J Goldstein, Mark N Feinglos, Jared K Lunceford, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 25, 2007
Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitroSrinivasa Raju Datla, Hitesh Peshavariya, Gregory J Dusting, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 23, 2008
Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: role of cAMP/PKA signalingShi-Qiong Xu, Kalyankar Mahadev, Xiangdong Wu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 31, 2015
Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trialsElizabeth S Ommen, Lei Xu, Edward A O'Neill, et al.
Pageof 8